Please provide your email address to receive an email when new articles are posted on . Adding itacitinib to standard prophylaxis may reduce GVHD incidence for patients who undergo haploidentical stem ...

Shi’s study, "Selective suppression of melanoma lacking IFN-γ pathway by JAK inhibition depends on T cells and host TNF signaling," was recently published in Nature Communications. “Concerted efforts ...

Checkpoint inhibitor therapies can be thought of as the molecular "brake release" for the immune system. These drugs eliminate the protein barriers that impede the immune system from recognizing and ...

Among 88 heavily pretreated patients evaluable for efficacy, 44% (95% CI 34-55) responded to single-agent golidocitinib, with 24% (95% CI 15-34) achieving a complete response, reported Jun Zhu, MD, of ...

Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced the expansion of its Scientific Advisory ...

A team of researchers at UCLA Health Jonsson Comprehensive Cancer Center has identified a potential new strategy to prevent, and potentially reverse, immune checkpoint inhibitor (ICI)–induced type I ...

DOVER, Del., Dec. 17, 2025 /PRNewswire/ -- Eilean Therapeutics announced the advancement of ZE74-0282 into first-in-human clinical development. ZE74-0282 is a novel, highly selective inhibitor of the ...